Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | TP53 | P04637 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.45 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731002 | 0.83 | F2RL3 (0.48) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL13729698 | 0.82 | KDM4E (0.41) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL13731007 | 0.81 | CSNK1D (0.35) | RAB9ANPC1TP53MAPTALDH1A3 | |
| SCHEMBL13730155 | 0.80 | F2RL3 (0.46) | RAB9ANPC1TP53MAPTPDE10A | |
| SCHEMBL13750723 | 0.79 | RAB9A (0.54) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL798826 | 0.78 | DYRK1A (0.34) | DYRK1A | |
| SCHEMBL10532301 | 0.77 | NPC1 (0.55) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL3108835 | 0.76 | NPC1 (0.54) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL14076027 | 0.76 | NPC1 (0.54) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL13744906 | 0.75 | NPC1 (0.53) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | RAB9A 3311/4885NPC1 730/4885TP53 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.